WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 205599
Description: PTC299, a VEGF inhibitor, is an orally bioavailable, small molecule inhibitor of vascular endothelial growth factor (VEGF) synthesis with potential antiangiogenesis and antineoplastic activities. VEGF inhibitor PTC299 targets post-transcriptionally by selectively binding the 5'- and 3'-untranslated regions (UTR) of VEGF messenger RNA (mRNA), thereby preventing translation of VEGF. This inhibits VEGF protein production and decreases its levels in the tumor and bloodstream. In turn, this may result in the inhibition of migration, proliferation and survival of endothelial cells, microvessel formation, the inhibition of tumor cell proliferation, and eventually the induction of tumor cell death.
MedKoo Cat#: 205599
PTC299 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to firstname.lastname@example.org to inquire quote.
Synonym: PTC299; PTC 299; PTC-299.
IUPAC/Chemical Name: chemical structure is not available at this time.
SMILES Code: chemical structure is not available at this time.
The following data is based on the product molecular weight Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Packer RJ, Rood BR, Turner DC, Stewart CF, Fisher M, Smith C, Young-Pouissant T, Goldman S, Lulla R, Banerjee A, Pollack I, Kun L, Onar-Thomas A, Wu S, Boyett JM, Fouladi M. Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study. J Neurooncol. 2015 Jan;121(1):217-24. doi: 0.1007/s11060-014-1665-1. Epub 2014 Nov 19. PubMed PMID: 25407389; PubMed Central PMCID: PMC4330963.
2: Fong B, Barkhoudarian G, Pezeshkian P, Parsa AT, Gopen Q, Yang I. The molecular biology and novel treatments of vestibular schwannomas. J Neurosurg. 2011 Nov;115(5):906-14. doi: 0.3171/2011.6.JNS11131. Epub 2011 Jul 29. Review. PubMed PMID: 21800959.
PTC299 is currently being developed for the treatment of cancer. It has completed Phase 1a trials in healthy volunteers, and is now being studied in a Phase 1-2 trials in patients with solid tumors, metastatic breast cancer and neurofibromatosis type 2. PTC299 was designed to inhibit VEGF production in tumors. Because PTC299 inhibits VEGF production, its action occurs at a different point in the VEGF pathway than other therapies. PTC299 may be active both as a single agent or when used in combination with other anti-angiogenic agents or with chemotherapy agents for the treatment of cancers. (source: http://www.ptcbio.com/ptc299).